Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Awwad

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Infectious Diseases (London, England)|February 1, 2021
Using external data to assess the external validity of a randomised controlled trialAdi Turjeman, Muhammad Awwad, Shachaf Shiber, et al.
Journal of Clinical Medicine|May 14, 2022
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 YearsErez Bar-Haim, Noa Eliakim-Raz, Amos Stemmer, et al.
Scientific Reports|November 5, 2024
Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional studyDana Yelin, Nassem Ghantous, Muhammad Awwad, et al.
BMJ Open|August 2, 2022
Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort studyNoa Eliakim-Raz, Amos Stemmer, Yaara Leibovici-Weisman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 3, 2022
Characteristics of long-COVID among older adults: a cross-sectional studyVered Daitch, Dana Yelin, Muhammad Awwad, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Infectious Diseases (London, England)|February 1, 2021
Using external data to assess the external validity of a randomised controlled trialAdi Turjeman, Muhammad Awwad, Shachaf Shiber, et al.
Journal of Clinical Medicine|May 14, 2022
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 YearsErez Bar-Haim, Noa Eliakim-Raz, Amos Stemmer, et al.
Scientific Reports|November 5, 2024
Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional studyDana Yelin, Nassem Ghantous, Muhammad Awwad, et al.
BMJ Open|August 2, 2022
Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort studyNoa Eliakim-Raz, Amos Stemmer, Yaara Leibovici-Weisman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 3, 2022
Characteristics of long-COVID among older adults: a cross-sectional studyVered Daitch, Dana Yelin, Muhammad Awwad, et al.
Pageof 1